Gastrointestinal (GI) adverse events (AEs) that occurred in patients with metastatic breast cancer who were treated with oral paclitaxel and encequidar can be managed by the use of 5- HT3 inhibitors and early intervention with loperamide, according to research presented at the 2020 San Antonio Breast Cancer Symposium.
A poster presented at the 2020 San Antonio Breast Cancer Symposium found a trend towards less frequent care refusal when a safety net hospital introduced nurse breast navigators.
The FDA issued an emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine for the prevention of SARS-CoV-2 (which causes the coronavirus) for people aged 16 years or older.
Recent research highlighted the need for reliable information to address the educational and psychosocial needs of patients with newly diagnosed metastatic breast cancer.
BNT162b2 is the first vaccine recommended in the United States for the prevention of COVID-19.
Patients who experienced breakthrough CINV in their first chemotherapy cycle were more likely to have the adverse event in later cycles too, recent research found.
Patients with chronic lymphocytic leukemia who received treatment with single-agent acalabrutinib experienced a low incidence of cardiac toxicities leading to treatment discontinuation.
Oral azacitidine improved overall survival and relapse-free survival, while maintaining health-related quality of life in patients with acute myeloid leukemia.
Patients with cancer may be more susceptible to COVID-19. As oncology nurses await the approval of a vaccine, they shared their thoughts with Oncology Nursing News.
Patients with aggressive lymphomas had a sharp increase in quality of life from time of diagnosis until 1 year later.
A recent study analyzed nurse and patient preference when it came to the administration of rituximab in patients with blood cancer.
Nurse stress can have trickle-down effects in the cancer setting, but certain interventions can help.
With the identification of actionable alterations, precision medicine continues to lead the way in all areas of oncology, but especially in melanoma, according to Jason J. Luke, MD, FACP, who added that, in order to successfully apply personalized therapy, it’s critical to be fluent in the differences between biomarkers.
Recent research found 4 common occurrences that can delay chemotherapy treatment in an outpatient setting.
The coronavirus disease 2019 (COVID-19) pandemic has become another potential complication for patients with lung cancer, said Mark G. Kris, MD, who added that although the pandemic has disrupted patient care, it has yet to stunt scientific collaboration.
The FDA has granted a priority review designation to the oral FGFR1-3 selective inhibitor infigratinib for the treatment of patients with cholangiocarcinoma.
What was the most noteworthy news in the oncology nursing arena this year? Take our survey and tell us what you think.
The FDA approved pralsetinib (Gavreto) for adults and children aged 12 or older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who need systemic therapy or RET fusion-positive thyroid cancer who require systemic therapy and are radioactive iodine-refractory.
The FDA approved Gallium 68 PSMA-11 (Ga 68 PSMA-11), a drug for PET imaging of prostate-specific membrane antigen (PSMA) positive levels in men with suspected prostate cancer metastasis, who may be curable by surgery or radiation therapy.
Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from November 2020.
The FDA has approved the Sonalleve MR-guided high-intensity focused ultrasound (MR-HIFU) system for the treatment of patients with osteoid osteoma in the extremities.
Following the approvals of tisagenlecleucel (tisa-cel; Kymriah) and axicabtagene ciloleucel (axi-cel; Yescarta), several research efforts have been dedicated to the development and exploration of CAR T-cell therapies in the realm of leukemias and lymphomas, according to Olalekan O. Oluwole, MBBS, MD, who added that although this modality has moved the needle forward, this approach is not without toxicity.
The advent of 3D printing has led to an exciting revolution in limb salvage surgery for patients with bone tumors and soft tissue sarcomas, and have resulted in more precise resection and high-fidelity reconstruction, according to R. Lor Randall, MD, FACS.
Nurses are much more than “doctors’ helpers,” and now the world is starting to see that.
The FDA has granted an accelerated approval to naxitamab-gqgk (Danyelza) for use in combination with granulocyte-macrophage colony-stimulating factor as a treatment for pediatric patients 1 year of age and older and adult patients with relapsed/refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior treatment.
The clinical trial planned to evaluate the targeted agent will focus on patients with relapsed/refractory clear cell sarcoma.
Tebentafusp (IMCgp100) showed superiority in overall survival (OS) compared with investigator’s choice of therapy in patients with previously untreated metastatic uveal melanoma, according to results of a preplanned interim analysis of the phase 3 IMCgp100-202 trial (NCT03070392).
To understand the impact of the pandemic, I asked clinical nurses to describe the 2020 The Year of the Nurse and Midwife in a few words. Everyone was eager to give a statement and many, many were very prideful for the nursing care done in 2020.
With additional JAK inhibitors under exploration in the myelofibrosis pipeline, such as momelotinib and pacritinib, FDA-approved options continue to be utilized heavily in the paradigm, explained John O. Mascarenhas, MD.
